Integrin beta-3 L33P: A new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy?

European Journal of Neurology

Volumn 17, Issue 7, 2010, Pages 963-968

  Antonacopoulou, A G ^a   Argyriou, A A ^a,b   Scopa, C D ^a   Kottorou, A ^a   Kominea, A ^c   Peroukides, S ^a   Kalofonos, H P ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^b Saint andrew'Cs'c State General Hospital of Patras   (United States)

^c Aegion General Hospital   (Greece)

Author keywords

biomarkers; integrin beta 3; neurotoxicity; oxaliplatin; pathogenesis; polymorphism

Indexed keywords

BETA3 INTEGRIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; ALLELE; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; OXALIPLATIN INDUCED PERIPHERAL NEUROPATHY; PATHOGENESIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; REAL TIME POLYMERASE CHAIN REACTION; SCORING SYSTEM;

AGED; ANTINEOPLASTIC AGENTS; CHRONIC DISEASE; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IATROGENIC DISEASE; INTEGRIN BETA3; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; PILOT PROJECTS; SEVERITY OF ILLNESS INDEX;

EID: 77953829803     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.02966.x     Document Type: Article

References (24)

1. Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 2008 34: 368 377.
2. Argyriou AA, Polychronopoulos P, Iconomou G, et al. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. Acta Oncol 2007 46: 1131 1137.
3. Hynes R. Integrins: bidirectional, allosteric signaling machines. Cell 2002 110: 673 687.
4. Vijayan KV, Goldschmidt-Clermont PJ, Roos C, Bray PF. The Pl(A2) polymorphism of integrin beta(3) enhances outside-in signaling and adhesive functions. J Clin Invest 2000 105: 793 802.
5. Vijayan KV, Liu Y, Sun W, Ito M, Bray PF. The Pro33 isoform of integrin beta3 enhances outside-in signaling in human platelets by regulating the activation of serine/threonine phosphatases. J Biol Chem 2005 280: 21756 21762.
6. Cavaletti G, Tredici G, Petruccioli MG, et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 2001 37: 2457 2463.
7. Cavaletti G, Jann S, Pace A, et al. Multi-center assessment of the total neuropathy score for chemotherapy-induced peripheral neurotoxicity. J Periph Nerv Syst. 2006 11: 135 141.
8. Cornblath DR, Chaudhry V, Carter K, et al. Total Neuropathy Score. Validation and reliability study. Neurology. 1999 53: 1660 1664.
9. Argyriou AA, Polychronopoulos P, Koutras A, et al. Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy. Eur J Cancer Care (Engl). 2007 16: 231 237.
10. Chaudhry V, Eisenberger MA, Sinibaldi VL, Sheikh K, Griffin JW, Cornblath DR. A prospective study of suramin-induced peripheral neuropathy. Brain. 1996 119: 101 114.
11. Cavaletti G, Bogliun G, Marzorati L, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the total neuropathy scale. Neurology. 2003 61: 1297 1300.
12. Smith EM, Beck SL, Cohen J. The total neuropathy score: a tool for measuring chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum 2008 35: 96 102.
13. Germer S, Higuchi R. Single-tube genotyping without oligonucleotide probes. Genome Res 1999 9: 72 78.
14. Grothey A, Goldberg RM. A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin Pharmacother 2004 5 (10 2159 2170.
15. Goodisman J, Hagrman D, Tacka KA, Souid AK. Analysis of cytotoxicities of platinum compounds. Cancer Chemother Pharmacol 2006 57 (2 257 267.
16. Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 2005 32: 51 60.
17. Grunberg SM, Sonka S, Stevenson LL, Muggia FM. Progressive paraesthesias after cessation of therapy with very high dose cisplatin. Cancer Chemother Pharmacol 1989 25: 62 64.
18. Cavaletti G, Miloso M, Nicolini G, Scuteri A, Tredici G. Emerging role of mitogen-activated protein kinases in peripheral neuropathies. J Peripher Nerv Syst. 2007 12: 175 194.
19. Pearson G, Robinson F, Beers Gibson T, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001 22: 153 183.
20. Gozdz A, Habas A, Jaworski J, et al. Role of N-methyl-D-aspartate receptors in the neuroprotective activation of extracellular signal-regulated kinase 1/2 by cisplatin. J Biol Chem 2003 278: 43663 43671.
21. Rosen LB, Ginty DD, Weber MJ, Greenberg ME. Membrane depolarization and calcium influx stimulate MEK and MAP kinase via activation of Ras. Neuron. 1994 12: 1207 1221.
22. Scuteri A, Galimberti A, Maggioni D, et al. Role of MAPKs in platinum-induced neuronal apoptosis. Neurotoxicology. 2009 30: 312 319.
23. Kirchmair R, Walter DH, Ii M, et al. Antiangiogenesis mediates cisplatin-induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth. Circulation 2005 111: 2662 2670.
24. Argyriou AA, Chroni E, Polychronopoulos P, et al. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology. 2006 67 (12 2253 2255.